Please login to the form below

Not currently logged in
Email:
Password:

Medivir buys BioPhausia

Medivir acquires BioPhausia in €62m deal as it looks to market new hepatitis C drug

Swedish company Medivir, which develops pharmaceuticals against infectious diseases caused by viruses, is to acquire specialty pharmaceutical company BioPhausia for SEK565 million (€62m).

Medivir says that the acquisition would provide it with a well-established commercial platform from which to launch its hepatitis C drug TMC435, which should be introduced on to the market by 2013.

Ron Long, chief executive of Medivir, said: "The task in hand for us is to put ourselves in a position where we can educate the market about the virtues and advantages of TMC435.”

Under the terms of the deal, Medivir is offering a mixture of cash and new shares.

13th April 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...